Annals of Surgical Oncology

, Volume 23, Issue 3, pp 722–728 | Cite as

Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020)

  • Faina Nakhlis
  • Lauren Gilmore
  • Rebecca Gelman
  • Isabelle Bedrosian
  • Kandice Ludwig
  • E. Shelley Hwang
  • Shawna Willey
  • Clifford Hudis
  • J. Dirk Iglehart
  • Elizabeth Lawler
  • Nicole Y. Ryabin
  • Mehra Golshan
  • Stuart J. Schnitt
  • Tari A. King
Breast Oncology

Abstract

Background

Lobular neoplasia (LN) represents a spectrum of atypical proliferative lesions, including atypical lobular hyperplasia and lobular carcinoma-in-situ. The need for excision for LN found on core biopsy (CB) is controversial. We conducted a prospective multi-institutional trial (TBCRC 20) to determine the rate of upgrade to cancer after excision for pure LN on CB.

Methods

Patients with a CB diagnosis of pure LN were prospectively identified and consented to excision. Cases with discordant imaging and those with additional lesions requiring excision were excluded. Upgrade rates to cancer were quantified on the basis of local and central pathology review. Confidence intervals and sample size were based on exact binomial calculations.

Results

A total of 77 of 79 registered patients underwent excision (median age 51 years, range 27–82 years). Two cases (3 %; 95 % confidence interval 0.3–9) were upgraded to cancer (one tubular carcinoma, one ductal carcinoma-in-situ) at excision per local pathology. Central pathology review of 76 cases confirmed pure LN in the CB in all but two cases. In one case, the tubular carcinoma identified at excision was also found in the CB specimen, and in the other, LN was not identified, yielding an upgrade rate of one case (1 %; 95 % CI 0.01–7) by central pathology review.

Conclusions

In this prospective study of 77 patients with pure LN on CB, the upgrade rate was 3 % by local pathology and 1 % by central pathology review, demonstrating that routine excision is not indicated for patients with pure LN on CB and concordant imaging findings.

References

  1. 1.
    Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17:491PubMedGoogle Scholar
  2. 2.
    Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004;100:238–44.CrossRefPubMedGoogle Scholar
  3. 3.
    Hoda SA (2001) Lobular carcinoma in situ and atypical lobular hyperplasia. In: Rosen PP, editor Rosen’s breast pathology, 2nd ed. Lippincott Williams & Wilkins, Philiadelphia, PA, pp. 581–618.Google Scholar
  4. 4.
    Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW Jr. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol. 1978;2:225–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Beute BJ, Kalisher L, Hutter RV. Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features. AJR Am J Roentgenol. 1991;157:257–65.CrossRefPubMedGoogle Scholar
  6. 6.
    Bauer VP, Ditkoff BA, Schnabel F, Brenin D, El-Tamer M, Smith S. The management of lobular neoplasia identified on percutaneous core breast biopsy. Breast J. 2003;9:4–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Foster MC, Helvie MA, Gregory NE, Rebner M, Nees AV, Paramagul C. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? Radiology. 2004;231:813–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Liberman L, Sama M, Susnik B, et al. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. AJR Am J Roentgenol. 1999;173:291–9.CrossRefPubMedGoogle Scholar
  9. 9.
    O’Driscoll D, Britton P, Bobrow L, Wishart GC, Sinnatamby R, Warren R. Lobular carcinoma in situ on core biopsy—what is the clinical significance? Clin Radiol. 2001;56:216–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Londero V, Zuiani C, Linda A, Vianello E, Furlan A, Bazzocchi M. Lobular neoplasia: core needle breast biopsy underestimation of malignancy in relation to radiologic and pathologic features. Breast. 2008;17:623–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Renshaw AA, Cartagena N, Derhagopian RP, Gould EW. Lobular neoplasia in breast core needle biopsy specimens is not associated with an increased risk of ductal carcinoma in situ or invasive carcinoma. Am J Clin Pathol. 2002;117:797–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Dmytrasz K, Tartter PI, Mizrachy H, Chinitz L, Rosenbaum Smith S, Estabrook A. The significance of atypical lobular hyperplasia at percutaneous breast biopsy. Breast J. 2003;9:10–2.CrossRefPubMedGoogle Scholar
  13. 13.
    Middleton LP, Grant S, Stephens T, Stelling CB, Sneige N, Sahin AA. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised? Mod Pathol. 2003;16:120–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM. Lobular neoplasia on core-needle biopsy—clinical significance. Cancer. 2004;101:242–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Crisi GM, Mandavilli S, Cronin E, Ricci A Jr. Invasive mammary carcinoma after immediate and short-term follow-up for lobular neoplasia on core biopsy. Am J Surg Pathol. 2003;27:325–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Irfan K, Brem RF. Surgical and mammographic follow-up of papillary lesions and atypical lobular hyperplasia diagnosed with stereotactic vacuum-assisted biopsy. Breast J. 2002;8:230–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Shin SJ, Rosen PP. Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med 2002;126(6):697−701PubMedGoogle Scholar
  18. 18.
    Yeh IT, Dimitrov D, Otto P, Miller AR, Kahlenberg MS, Cruz A. Pathologic review of atypical hyperplasia identified by image-guided breast needle core biopsy. Correlation with excision specimen. Arch Pathol Lab Med. 2003;127:49–54.PubMedGoogle Scholar
  19. 19.
    Hwang H, Barke LD, Mendelson EB, Susnik B. Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary. Mod Pathol. 2008;21:1208–16.CrossRefPubMedGoogle Scholar
  20. 20.
    Bonnett M, Wallis T, Rossmann M, et al. Histopathologic analysis of atypical lesions in image-guided core breast biopsies. Mod Pathol. 2003;16:154–60.CrossRefPubMedGoogle Scholar
  21. 21.
    El-Sheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol. 2005;29:534–43.CrossRefGoogle Scholar
  22. 22.
    Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 2.2015. J Natl Compr Canc Netw. 2015;13:448–75.PubMedGoogle Scholar
  23. 23.
    Atkins KA, Cohen MA, Nicholson B, Rao S. Atypical lobular hyperplasia and lobular carcinoma in situ at core breast biopsy: use of careful radiologic-pathologic correlation to recommend excision or observation. Radiology. 2013;269:340–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Cangiarella J, Guth A, Axelrod D, et al. Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core needle biopsy? A report of 38 cases and review of the literature. Arch Pathol Lab Med. 2008;132:979–83.PubMedGoogle Scholar
  25. 25.
    Chaudhary S, Lawrence L, McGinty G, Kostroff K, Bhuiya T. Classic lobular neoplasia on core biopsy: a clinical and radio-pathologic correlation study with follow-up excision biopsy. Mod Pathol. 2013;26:762–71.CrossRefPubMedGoogle Scholar
  26. 26.
    Lewis JL, Lee DY, Tartter PI. The significance of lobular carcinoma in situ and atypical lobular hyperplasia of the breast. Ann Surg Oncol. 2012;19:4124–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Nagi CS, O’Donnell JE, Tismenetsky M, Bleiweiss IJ, Jaffer SM. Lobular neoplasia on core needle biopsy does not require excision. Cancer. 2008;112:2152–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Niell B, Specht M, Gerade B, Rafferty E. Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR Am J Roentgenol. 2012;199:929–35.CrossRefPubMedGoogle Scholar
  29. 29.
    Rendi MH, Dintzis SM, Lehman CD, Calhoun KE, Allison KH. Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol. 2012;19:914–21.CrossRefPubMedGoogle Scholar
  30. 30.
    Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, Deperi ER, Glazebrook KN. Longterm follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol. 2012;19:3131–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Zhao C, Desouki MM, Florea A, Mohammed K, Li X, Dabbs D. Pathologic findings of follow-up surgical excision for lobular neoplasia on breast core biopsy performed for calcification. Am J Clin Pathol. 2012;138:72–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Murray MP, Luedtke C, Liberman L, Nehhozina T, Akram M, Brogi E. Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer. 2013;119:1073–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Gomes DS, Porto SS, Balabram D, Gobbi H. Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Diagn Pathol. 2014;9:121.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136:627–33.CrossRefPubMedGoogle Scholar
  35. 35.
    Barr RG, Zhang Z, Cormack JB, Mendelson EB, Berg WA. Probably benign lesions at screening breast US in a population with elevated risk: prevalence and rate of malignancy in the ACRIN 6666 trial. Radiology. 2013;269:701–12.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Faina Nakhlis
    • 1
    • 8
  • Lauren Gilmore
    • 2
  • Rebecca Gelman
    • 1
  • Isabelle Bedrosian
    • 4
  • Kandice Ludwig
    • 5
  • E. Shelley Hwang
    • 6
  • Shawna Willey
    • 7
  • Clifford Hudis
    • 3
  • J. Dirk Iglehart
    • 1
    • 8
  • Elizabeth Lawler
    • 1
  • Nicole Y. Ryabin
    • 1
  • Mehra Golshan
    • 1
    • 8
  • Stuart J. Schnitt
    • 9
  • Tari A. King
    • 10
  1. 1.Dana-Farber/Harvard Cancer CenterBostonUSA
  2. 2.Mount Auburn HospitalCambridgeUSA
  3. 3.Breast Medicine Service, Department of MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.University of Texas MD Anderson Cancer CenterHoustonUSA
  5. 5.Indiana University Cancer CenterIndianapolisUSA
  6. 6.Duke University Medical CenterDurhamUSA
  7. 7.Georgetown University Cancer CenterWashingtonUSA
  8. 8.Dana-Farber/Brigham and Women’s Cancer CenterBostonUSA
  9. 9.Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA
  10. 10.Breast Service, Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations